Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. (PubMed, Cancer Chemother Pharmacol) - Sep 25, 2026 - P1/2 | "With the proposed starting dose of 200 mg QD, most patients (96%) were expected to exceed 90% BTK inhibition, across the entire dosing interval, indicating extensive and durable engagement of the drug target. No dose adjustments based on body weight, serum albumin or renal function were recommended."
Journal • P1/2 data • PK/PD data • Hematological Disorders • Hematological Malignancies • Hepatology • Oncology
|
|
Dan Liu; Eunice Yuen; Lisa M O'Brien; Robert Bell; Sonya C Chapman
|